Neuromelanin in parkinsonian disorders: an update

References

• Zecca L, Stroppolo A, Gatti A, et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A 2004;101:9843–8.
   PubMed Web of Science ®Google Scholar
• Fedorow H, Tribl F, Halliday G, et al. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol 2005;75:109–24.
   PubMed Web of Science ®Google Scholar
• Zecca L, Bellei C, Costi P, et al. New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals. Proc Natl Acad Sci U S A 2008;105:17567–72.
   PubMed Web of Science ®Google Scholar
• Engelen M, Vanna R, Bellei C, et al. Neuromelanins of human brain have soluble and insoluble components with dolichols attached to the melanic structure. PLoS One 2012;7:e48490.
   PubMed Web of Science ®Google Scholar
• Sulzer D, Mosharov E, Talloczy Z, et al. Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease. J Neurochem 2008;106:24–36.
   PubMed Web of Science ®Google Scholar
• Ferrari E, Capucciati A, Prada I, et al. Synthesis, structure characterization, and evaluation in microglia cultures of neuromelanin analogues suitable for modeling Parkinson's disease. ACS Chem Neurosci 2017;8:501–12.
   PubMed Web of Science ®Google Scholar
• Zecca L, Costi P, Mecacci C, et al. Interaction of human substantia nigra neuromelanin with lipids and peptides. J Neurochem 2000;74:1758–65.
   PubMed Web of Science ®Google Scholar
• Zucca FA, Segura-Aguilar J, Ferrari E, et al. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog Neurobiol 2015: S0301-0082(15)00101-X 10.1016.
   PubMed Web of Science ®Google Scholar
• Sulzer D, Bogulavsky J, Larsen KE, et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci U S A 2000;97:11869–74.
   PubMed Web of Science ®Google Scholar
• Fedorow H, Halliday GM, Rickert CH, et al. Evidence for specific phases in the development of human neuromelanin. Neurobiol Aging 2006;27:506–12.
   PubMed Web of Science ®Google Scholar
• Zecca L, Pietra R, Goj C, et al. Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J Neurochem 1994;62:1097–1101.
   PubMed Web of Science ®Google Scholar
• Zecca L, Tampellini D, Costi P, et al. Combined biochemical separation and INAA for the determination of iron and other metals in neuromelanin of human brain substantia nigra. J Radioanal Nucl Ch 2001;249:449–54.
   Web of Science ®Google Scholar
• Shima T, Sarna T, Swartz HM, et al. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Radical Bio Med 1997;23:110–19.
   PubMed Web of Science ®Google Scholar
• Zecca L, Casella L, Albertini A, et al. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J Neurochem 2008;106:1866–75.
   PubMed Web of Science ®Google Scholar
• Fasano M, Bergamasco B, Lopiano L. Is neuromelanin changed in Parkinson's disease? Investigations by magnetic spectroscopies. J Neural Transm 2006;113:769–74.
   PubMed Web of Science ®Google Scholar
• Ito S. Encapsulation of a reactive core in neuromelanin. Proc Natl Acad Sci U S A 2006;103:14647–8.
   PubMed Web of Science ®Google Scholar
• Lindquist NG, Larsson BS, Lydensokolowski A. Autoradiography of [C-14] Paraquat or [C-14] Diquat in frogs and mice – accumulation in neuromelanin. Neurosci Lett 1988;93:1–6.
   PubMed Web of Science ®Google Scholar
• Karlsson O, Lindquist NG. Melanin and neuromelanin binding of drugs and chemicals: toxicological implications. Arch Toxicol 2016;90:1883–91.
   PubMed Web of Science ®Google Scholar
• Wilms H, Rosenstiel P, Sievers J, et al. Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J 2003;17:500–2.
   PubMed Web of Science ®Google Scholar
• Zhang W, Phillips K, Wielgus AR, et al. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res 2011;19:63–72.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zecca L, Wielgus B, et al. Human neuromelanin: an endogenous microglial activator for dopaminergic neuron death. Front Biosci (Elite edition) 2013;5:1–11.
   PubMedGoogle Scholar
• Shamoto-Nagai M, Maruyama W, Akao Y, et al. Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells. J Neural Transm 2004;111:1253–65.
   PubMed Web of Science ®Google Scholar
• Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic-neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334:345–48.
   PubMed Web of Science ®Google Scholar
• Yamada T, Mcgeer PL, Baimbridge KG, et al. Relative sparing in Parkinson's disease of substantia-nigra dopamine neurons containing calbindin-D28k. Brain Res 1990;526:303–7.
   PubMed Web of Science ®Google Scholar
• Gibb WRG, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia-nigra, and differential cell-death in Parkinson's disease. J Neurol Neurosur Psychiatry 1991;54:388–96.
   PubMed Web of Science ®Google Scholar
• Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283–2301.
   PubMed Web of Science ®Google Scholar
• Rudow G, O'Brien R, Savonenko AV, et al. Morphometry of the human substantia nigra in ageing and Parkinson's disease. Acta Neuropathol (Berl) 2008;115:461–70.
   PubMed Web of Science ®Google Scholar
• Damier P, Hirsch EC, Agid Y, et al. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999;122(Pt 8):1437–48.
   PubMed Web of Science ®Google Scholar
• Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013;136:2419–31.
   PubMed Web of Science ®Google Scholar
• Enochs WS, Petherick P, Bogdanova A, et al. Paramagnetic metal scavenging by melanin: MR imaging. Radiology 1997;204:417–23.
   PubMed Web of Science ®Google Scholar
• Trujillo P, Summers PE, Ferrari E, et al. Contrast mechanisms associated with neuromelanin-MRI. Magn Reson Med 2016. doi:10.1002/mrm.26584
   Web of Science ®Google Scholar
• Sasaki M, Shibata E, Tohyama K, et al. Neuromelanin magnetic resonance imaging of locus coeruleus and substantia nigra in Parkinson's disease. Neuroreport 2006;17:1215–8.
   PubMed Web of Science ®Google Scholar
• Kashihara K, Shinya T, Higaki F. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. J Clin Neurosci 2011;18:1093–6.
   PubMed Web of Science ®Google Scholar
• Schwarz ST, Rittman T, Gontu V, et al. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Mov Disord 2011;26:1633–8.
   PubMed Web of Science ®Google Scholar
• Ohtsuka C, Sasaki M, Konno K, et al. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging. Neurosci Lett 2013;541:93–8.
   PubMed Web of Science ®Google Scholar
• Ogisu K, Kudo K, Sasaki M, et al. 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease. Neuroradiology 2013;55:719–24.
   PubMed Web of Science ®Google Scholar
• Reimao S, Pita Lobo P, Neutel D, et al. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients. Eur J Neurol 2015;22:540–6.
   PubMed Web of Science ®Google Scholar
• Reimao S, Pita Lobo P, Neutel D, et al. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease. Mov Disord 2015;30:953–9.
   PubMed Web of Science ®Google Scholar
• Castellanos G, Fernandez-Seara MA, Lorenzo-Betancor O, et al. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease. Mov Disord 2015;30:945–52.
   PubMed Web of Science ®Google Scholar
• Reimao S, Ferreira S, Nunes RG, et al. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease. Eur J Neurol 2016;23:368–74.
   PubMed Web of Science ®Google Scholar
• Isaias IU, Trujillo P, Summers P, et al. Neuromelanin imaging and dopaminergic loss in Parkinson's disease. Front Aging Neurosci 2016;8:196.
   PubMed Web of Science ®Google Scholar
• Garcia-Lorenzo D, Longo-Dos Santos C, Ewenczyk C, et al. The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease. Brain 2013;136:2120–9.
   PubMed Web of Science ®Google Scholar
• Kashihara K, Shinya T, Higaki F. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD. Internal Med 2011;50:1683–7.
   PubMed Web of Science ®Google Scholar
• Ohtsuka C, Sasaki M, Konno K, et al. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord 2014;20:755–60.
   PubMed Web of Science ®Google Scholar
• Matsuura K, Maeda M, Yata K, et al. Neuromelanin magnetic resonance imaging in Parkinson's disease and multiple system atrophy. Eur Neurol 2013;70:70–7.
   PubMed Web of Science ®Google Scholar
• Mukai M, Sugaya K, Yabe I, et al. Neuromelanin MRI in a family with mitochondrial parkinsonism harboring a Y955C mutation in POLG1. Parkinsonism Relat Disord 2013;19:821–4.
   PubMed Web of Science ®Google Scholar